Aurinia Pharmaceuticals Inc. (AUPH) Stock: Here’s Why It’s Climbing


Aurinia Pharmaceuticals Inc. (AUPH) is headed up in the market in today’s trading session. The company, focused in the biotech industry, is presently trading at $6.88 after a move up of 7.17% so far in today’s session. In terms of biotech stocks, there are a number of aspects that have the potential to lead to gains in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines centered around AUPH:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 10:14PM Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
04:14PM Aurinia: 4Q Earnings Snapshot
04:02PM Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
02:30PM Aurinia Pharmaceuticals Inc. to Host Earnings Call
Mar-14-19 07:00AM Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

However, any time investors are making a decision to invest, investors should look at much more than news, especially in the highly speculative biotech industry. Here’s what’s going on with Aurinia Pharmaceuticals Inc..

What We’ve Seen From AUPH

Although a single session gain, like what we’re seeing from Aurinia Pharmaceuticals Inc. might cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always smart to look into trends experienced by the stock for a period longer than a single trading session. In the case of AUPH, here are the returns on investment that investors have seen:

  • Past 7 Days – Over the last week, AUPH has seen a change in value amounting to 2.39%.
  • Past 30 Days – The monthly returns from Aurinia Pharmaceuticals Inc. works out to -2.87%.
  • Past Three Months – Throughout the past quarter, the company has produced a return on investment that works out to 6.82%
  • Bi-Annually – Throughout the past six months, we’ve seen a performance of 13.83% from the company.
  • Year To Date – Since the the first trading session of this year AUPH has resulted in a return of -5.87%.
  • Full Year – Finally, over the last year, we’ve seen movement of 12.43% out of AUPH. In this period, the stock has traded at a high of -12.36% and a low of 37.33%.

Ratios That Are Notable

Digging into a few key ratios associated with a stock can provide traders a look of just how risky and/or potentially profitable a an investment option may be. Below are some of the key ratios to think about when looking at AUPH.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it shows that more investors have a belief that the stock is going to go down. Across the sector, biotechnology stocks tend to carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, with regard to Aurinia Pharmaceuticals Inc., the stock’s short ratio clocks in at 5.58.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure If a company is able to cover its debts as they mature with only quick assets or current assets. In the biotechnology sector, several companies rely on continued support from investors, the current and quick ratios can look bad. However, some good picks in the biotech space do have great quick and current ratios. As far as AUPH, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the share price. In this case, that ratio works out to 1.47.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.

What Analysts Say About Aurinia Pharmaceuticals Inc.

Although it’s rarely a good idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their thoughts in order to validate your own thoughts before making an investment decision in the biotech industry. Here are the recent moves that we’ve seen from analysts as it relates to AUPH.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-16-18 Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18 Initiated RBC Capital Mkts Outperform $9
Oct-30-17 Reiterated H.C. Wainwright Buy $10 → $12
May-18-17 Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17 Initiated Cantor Fitzgerald Overweight $14

Smart Money Follows Big Money

An interesting fact that I’ve come to understand so far in my short period as an intelligence is that smart money tends to follow big money investors. Usually, investors that are looking to keep their investments relatively safe will keep an eye on moves made by institutional investors and insiders of the company. So, how does the big money flow when it comes to AUPH? Here’s what’s happening:

  • Institutions – At the moment, institutional investors hold 0 of AUPH. Nonetheless, it is worth mentioning that the ownership held by institutions has changed in the amount of 0 in the past quarter.
  • Insider Moves – As far as insiders go, members of the management team and others close to AUPH currently hold 0 of the company. Insider ownership of the company has seen a change of 0 over the past 3 months.

Looking At Share Counts

Investors tend to have an interest in the counts of shares both outstanding and available. In terms of Aurinia Pharmaceuticals Inc., there are currently 85.34M with a float of 63.05M. These data mean that out of the total of 85.34M shares of AUPH that are out there today, 63.05M are available to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AUPH, the short percent of the float is 9.46%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.55. In the current quarter, analysts see the company producing earnings in the amount of $-0.15. Over the last 5 years, AUPH has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 1193.10%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here